Mylan launches review to unlock firm’s“true value”
This article was originally published in OTC Bulletin & The Rose Sheet
Mylan has put together a board committee which is “actively evaluating a wide range of alternatives to unlock the true value of our one-of-a-kind platform”. Describing current “negative trends and dynamics” in the US as “unsustainable for the US healthcare system”, Mylan insisted investors “under-appreciate and under-value the durability, differentiation and strengths of Mylan’s global diversified business”.
You may also be interested in...
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.